NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis $333.91 -6.89 (-2.02%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDGL alerts:Sign Up Key Stats Today's Range$331.25▼$345.7350-Day Range$295.02▼$355.8852-Week Range$200.08▼$377.46Volume416,600 shsAverage Volume387,235 shsMarket Capitalization$7.37 billionP/E RatioN/ADividend YieldN/APrice Target$409.00Consensus RatingBuy Company OverviewMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Read More… Madrigal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreMDGL MarketRank™: Madrigal Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 286th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMadrigal Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($23.47) to ($12.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 16.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.94% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 0.75%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.92 Percentage of Shares Shorted23.94% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 0.75%, indicating that investor sentiment is decreasing. News and Social Media3.6 / 5News Sentiment1.44 News SentimentMadrigal Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Madrigal Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest11 people have searched for MDGL on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,610,594.00 in company stock.Percentage Held by Insiders22.80% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Stock News HeadlinesMadrigal stock holds neutral as 1Q revenue beats estimatesApril 30 at 9:00 PM | investing.comUncovering Potential: Madrigal Pharmaceuticals's Earnings PreviewApril 30 at 3:59 PM | benzinga.comThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.April 30, 2025 | Weiss Ratings (Ad)Madrigal Pharmaceuticals, Inc. Q1 2025 Earnings PreviewApril 30 at 3:59 PM | msn.comMadrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL CongressApril 29 at 8:00 AM | globenewswire.comTD Cowen Remains a Buy on Madrigal Pharmaceuticals (MDGL)April 23, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals to Announce Q1 2025 Results with Live WebcastApril 20, 2025 | msn.comAnalysts Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Price Target at $378.44April 20, 2025 | americanbankingnews.comSee More Headlines MDGL Stock Analysis - Frequently Asked Questions How have MDGL shares performed this year? Madrigal Pharmaceuticals' stock was trading at $308.57 at the beginning of 2025. Since then, MDGL stock has increased by 8.2% and is now trading at $333.91. View the best growth stocks for 2025 here. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($2.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.32) by $1.61. The biopharmaceutical company had revenue of $103.32 million for the quarter, compared to analysts' expectations of $97.81 million. Read the conference call transcript. Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (0.32%), Bank of New York Mellon Corp (0.28%), Rheos Capital Works Inc. (0.20%) and GAMMA Investing LLC (0.18%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Paul A Friedman, William John Sibold, Brian Joseph Lynch, Richard S Levy, Fred B Craves, Carole Huntsman, Shannon T Kelley, Robert E Waltermire, James M Daly and Remy Sukhija. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY). Company Calendar Last Earnings2/26/2025Today4/30/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees90Year Founded2011Price Target and Rating Average Stock Price Target$409.00 High Stock Price Target$469.00 Low Stock Price Target$350.00 Potential Upside/Downside+19.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($22.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-373,630,000.00 Net MarginsN/A Pretax Margin-675.24% Return on Equity-71.78% Return on Assets-53.25% Debt Debt-to-Equity Ratio0.15 Current Ratio5.98 Quick Ratio5.93 Sales & Book Value Annual Sales$180.13 million Price / Sales42.11 Cash FlowN/A Price / Cash FlowN/A Book Value$20.53 per share Price / Book16.73Miscellaneous Outstanding Shares22,080,000Free Float16,837,000Market Cap$7.58 billion OptionableOptionable Beta-0.69 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:MDGL) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.